Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled dose escalation Phase I study to evaluating the safety, tolerability, pharmacokinetics and immunogenicity of IMG-008 in healthy adult subjects

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled dose escalation Phase I study to evaluating the safety, tolerability, pharmacokinetics and immunogenicity of IMG-008 in healthy adult subjects

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMG 008 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

Most Recent Events

  • 12 Feb 2023 According to an Inmagene media release, company announced that the U.S. Food and Drug Administration (FDA) recently granted the initial investigational new drug (IND) application for its drug candidate IMG-008
  • 11 Feb 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top